Arno Therapeutics (ARNI) 1.3500 $ARNI
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Dr. Alex Zukiwski is scheduled to present at the 13 Annual BIO Investor Forum, being held October 7-8, 2014 at The Palace Hotel in San Francisco, CA.
Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014
GlobeNewswire - Thu Sep 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected as Chair of World CDx Boston 2014, the 5 annual summit of this meeting, being held September 23-25, 2014 in Boston, Mass.
Arno Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Dr. Alex Zukiwski, Chief Executive Officer and Mr. Lawrence Kenyon, Chief Financial Officer, are scheduled to present at the 16 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2014 in New York and the Aegis Capital 2014 Healthcare & Technology Conference being held September 10-13, 2014 in Las Vegas.
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
GlobeNewswire - Thu Aug 14, 3:49PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the second quarter of 2014 and provided an update on recent clinical developments.
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
GlobeNewswire - Fri Jul 18, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the Company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities.
Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
GlobeNewswire - Tue Apr 01, 8:26AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the full year ended December 31, 2013. For the year ended December 31, 2013, Arno reported a net loss of $39.7 million, or $5.28 per share, which includes $19.0 million related to non-cash interest expense from convertible debentures retired in 2013, $4.2 million of non-cash other expense for the increase in derivative liability of stock warrants, and $1.5 million of non-cash stock based compensation expense. Adjusting for these non-cash items, which totaled $24.7 million, the Company realized a net loss of $15.0 million on a non-GAAP basis, or $2.00 per share. This compares to full year 2012 net loss of $14.4 million, or $3.17 per share on a GAAP basis, and adjusted 2012 net loss of $10.2 million on a non-GAAP basis, or $2.25 per share, when considering the same non-cash adjustments.
Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
GlobeNewswire - Wed Mar 26, 7:46AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new data from three research programs which support its investigational lead compound onapristone to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2014, being held April 5-9 in San Diego, California.
Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has appointed Randy H. Thurman as Vice Chairman of the Company's Board of Directors. Along with Arno's Chairman Dr. Arie Belldegrun, Mr. Thurman, who joined the Board in January 2013, will serve on the executive committee and work with the Company's leadership team to focus on the development of Arno's oncology pipeline, business development strategies and other key operational initiatives.
Arno Therapeutics to Present at 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:45AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.
Arno Therapeutics signs licensing agreement with University of Minnesota for use of oncology technology
M2 - Wed Mar 05, 5:44AM CST
US-based biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) said on Tuesday that it has entered into an exclusive, worldwide license agreement with the University of Minnesota to investigate the gene expression signature derived from archived breast cancer tissue samples.
Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
GlobeNewswire - Tue Mar 04, 7:32AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an exclusive, worldwide license agreement with the University of Minnesota for technology related to a gene expression signature derived from archived breast cancer tissue samples. This technique has the potential to identify progesterone-stimulated pathway activation and in turn, help identify patients who would most likely benefit from treatment with Arno's lead compound, onapristone, an anti-progestin therapeutic aimed at treatment of men's and women's cancers.
Arno Therapeutics names Lawrence A Kenyon as CFO
M2 - Fri Feb 28, 3:27AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) revealed on Thursday the addition of Lawrence A Kenyon as its chief financial officer.
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
GlobeNewswire - Thu Feb 27, 9:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has expanded its management team with the appointment of Lawrence A. Kenyon as Chief Financial Officer. Mr. Kenyon will report to President and Chief Executive Officer Glenn Mattes, and will direct financial reporting and controls. During a finance and accounting career spanning 25 years, Mr. Kenyon has spent over a decade leading the financial function at publicly-traded healthcare companies including several in the oncology space.
Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
GlobeNewswire - Tue Jan 21, 11:06AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors. The Phase I trial is designed to identify the recommended Phase II dose and determine the overall safety profile of onapristone.
Arno Therapeutics Inc submits IMPD to ANSM for planned Phase I trial of onapristone in PR positive tumors trial
M2 - Tue Sep 10, 8:59AM CDT
Biopharmaceutical company Arno Therapeutics Inc (OTC Markets:ARNI) revealed on Monday the submission of an Investigational Medicinal Product Dossier (IMPD) to request the clinical trial authorisation of a Phase I dose escalation study evaluating its lead compound onapristone in progesterone receptor positive tumors in post-menopausal women.
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
GlobeNewswire - Mon Sep 09, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno's lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.
Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance
GlobeNewswire - Wed Aug 21, 8:06AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has initiated a pharmacokinetic (PK) study of onapristone. The initiation follows the submission and approval of an Investigational Medicinal Product Dossier (IMPD) by the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM).
Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
GlobeNewswire - Mon Jun 03, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Veridex, LLC, a Johnson & Johnson company, to develop a diagnostic test to detect the presence of activated progesterone receptors (APRs) as a potential biomarker of anti-progestin activity in circulating tumor cells (CTCs). The diagnostic will help identify patients whom could potentially benefit from treatment with anti-progestins including onapristone, an orally-administered, investigational type 1 progestin receptor antagonist being developed by Arno.
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
PR Newswire - Wed May 15, 5:00PM CDT
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being held May 31-June 4, 2013 in Chicago, Illinois.
Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic Test
GlobeNewswire - Fri May 10, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Clarient Diagnostic Services, Inc., a GE Healthcare company, and leading provider of cancer diagnostic testing, to develop a diagnostic test to identify activated progesterone receptors in endometrial cancer. The diagnostic test is intended to be used in the development of Arno's investigational progestin receptor antagonist, onapristone. In pre-clinical studies, the presence of activated progesterone receptors (APR) has shown to be predictive of onapristone activity.
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Dr. Alex Zukiwski is scheduled to present at the 13 Annual BIO Investor Forum, being held October 7-8, 2014 at The Palace Hotel in San Francisco, CA.
Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014
GlobeNewswire - Thu Sep 18, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that David Jackson, Ph.D., Vice President of Diagnostics & Companion Diagnostics, has been selected as Chair of World CDx Boston 2014, the 5 annual summit of this meeting, being held September 23-25, 2014 in Boston, Mass.
Arno Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Dr. Alex Zukiwski, Chief Executive Officer and Mr. Lawrence Kenyon, Chief Financial Officer, are scheduled to present at the 16 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2014 in New York and the Aegis Capital 2014 Healthcare & Technology Conference being held September 10-13, 2014 in Las Vegas.
Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
GlobeNewswire - Thu Aug 14, 3:49PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the second quarter of 2014 and provided an update on recent clinical developments.
Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
GlobeNewswire - Fri Jul 18, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the Company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities.
Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
GlobeNewswire - Tue Apr 01, 8:26AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the full year ended December 31, 2013. For the year ended December 31, 2013, Arno reported a net loss of $39.7 million, or $5.28 per share, which includes $19.0 million related to non-cash interest expense from convertible debentures retired in 2013, $4.2 million of non-cash other expense for the increase in derivative liability of stock warrants, and $1.5 million of non-cash stock based compensation expense. Adjusting for these non-cash items, which totaled $24.7 million, the Company realized a net loss of $15.0 million on a non-GAAP basis, or $2.00 per share. This compares to full year 2012 net loss of $14.4 million, or $3.17 per share on a GAAP basis, and adjusted 2012 net loss of $10.2 million on a non-GAAP basis, or $2.25 per share, when considering the same non-cash adjustments.
Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
GlobeNewswire - Wed Mar 26, 7:46AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new data from three research programs which support its investigational lead compound onapristone to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2014, being held April 5-9 in San Diego, California.
Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has appointed Randy H. Thurman as Vice Chairman of the Company's Board of Directors. Along with Arno's Chairman Dr. Arie Belldegrun, Mr. Thurman, who joined the Board in January 2013, will serve on the executive committee and work with the Company's leadership team to focus on the development of Arno's oncology pipeline, business development strategies and other key operational initiatives.
Arno Therapeutics to Present at 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:45AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.
Arno Therapeutics signs licensing agreement with University of Minnesota for use of oncology technology
M2 - Wed Mar 05, 5:44AM CST
US-based biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) said on Tuesday that it has entered into an exclusive, worldwide license agreement with the University of Minnesota to investigate the gene expression signature derived from archived breast cancer tissue samples.
Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
GlobeNewswire - Tue Mar 04, 7:32AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an exclusive, worldwide license agreement with the University of Minnesota for technology related to a gene expression signature derived from archived breast cancer tissue samples. This technique has the potential to identify progesterone-stimulated pathway activation and in turn, help identify patients who would most likely benefit from treatment with Arno's lead compound, onapristone, an anti-progestin therapeutic aimed at treatment of men's and women's cancers.
Arno Therapeutics names Lawrence A Kenyon as CFO
M2 - Fri Feb 28, 3:27AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) revealed on Thursday the addition of Lawrence A Kenyon as its chief financial officer.
Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
GlobeNewswire - Thu Feb 27, 9:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has expanded its management team with the appointment of Lawrence A. Kenyon as Chief Financial Officer. Mr. Kenyon will report to President and Chief Executive Officer Glenn Mattes, and will direct financial reporting and controls. During a finance and accounting career spanning 25 years, Mr. Kenyon has spent over a decade leading the financial function at publicly-traded healthcare companies including several in the oncology space.
Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
GlobeNewswire - Tue Jan 21, 11:06AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors. The Phase I trial is designed to identify the recommended Phase II dose and determine the overall safety profile of onapristone.
Arno Therapeutics Inc submits IMPD to ANSM for planned Phase I trial of onapristone in PR positive tumors trial
M2 - Tue Sep 10, 8:59AM CDT
Biopharmaceutical company Arno Therapeutics Inc (OTC Markets:ARNI) revealed on Monday the submission of an Investigational Medicinal Product Dossier (IMPD) to request the clinical trial authorisation of a Phase I dose escalation study evaluating its lead compound onapristone in progesterone receptor positive tumors in post-menopausal women.
Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
GlobeNewswire - Mon Sep 09, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno's lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.
Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance
GlobeNewswire - Wed Aug 21, 8:06AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has initiated a pharmacokinetic (PK) study of onapristone. The initiation follows the submission and approval of an Investigational Medicinal Product Dossier (IMPD) by the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM).
Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
GlobeNewswire - Mon Jun 03, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Veridex, LLC, a Johnson & Johnson company, to develop a diagnostic test to detect the presence of activated progesterone receptors (APRs) as a potential biomarker of anti-progestin activity in circulating tumor cells (CTCs). The diagnostic will help identify patients whom could potentially benefit from treatment with anti-progestins including onapristone, an orally-administered, investigational type 1 progestin receptor antagonist being developed by Arno.
Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
PR Newswire - Wed May 15, 5:00PM CDT
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being held May 31-June 4, 2013 in Chicago, Illinois.
Arno Therapeutics to Collaborate With Clarient for Development of Diagnostic Test
GlobeNewswire - Fri May 10, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Clarient Diagnostic Services, Inc., a GE Healthcare company, and leading provider of cancer diagnostic testing, to develop a diagnostic test to identify activated progesterone receptors in endometrial cancer. The diagnostic test is intended to be used in the development of Arno's investigational progestin receptor antagonist, onapristone. In pre-clinical studies, the presence of activated progesterone receptors (APR) has shown to be predictive of onapristone activity.
